QT
RLMD icon

Quantbot Technologies’s Relmada Therapeutics RLMD Stock Holding History

Quantbot Technologies’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,516
Closed -$4.55K – 1926
2023
Q3 		$4.55K Sell
1,516
-229
-13% -$680 ﹤0.01% 1451
2023
Q2 		$4.29K Buy
1,745
+113
+7% +$312 ﹤0.01% 1493
2023
Q1 		$3.69K Sell
1,632
-4,516
-73% -$15.6K ﹤0.01% 1455
2022
Q4 		$21.5K Buy
+6,148
New +$54K ﹤0.01% 1438
2022
Q2 		– Sell
-1,100
Closed -$29K – 2064
2022
Q1 		$29K Sell
1,100
-417
-27% -$8.62K ﹤0.01% 1304
2021
Q4 		$34K Sell
1,517
-1,900
-56% -$42.3K ﹤0.01% 1129
2021
Q3 		$89K Buy
+3,417
New +$91.5K 0.01% 990

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Quantbot Technologies's RLMD Position: Q4 2023 in Review

Quantbot Technologies sold out of Relmada Therapeutics (RLMD) in Q4 2023, closing a stake of 1,516 shares — an estimated $4.55K sold.

Quantbot Technologies first reported a position in RLMD in Q3 2021 and held it in 7 quarters. The position peaked at $89K in Q3 2021. 83 funds tracked by Wall St. Rank hold RLMD as of Q4 2023.

  • Quantbot Technologies reported no remaining Relmada Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Quantbot Technologies sold 1,516 Relmada Therapeutics shares in Q4 2023, an estimated $4.55K.
  • Quantbot Technologies first reported a position in Relmada Therapeutics in Q3 2021 and held it in 7 quarters.
  • Quantbot Technologies's Relmada Therapeutics position peaked at $89K in Q3 2021.
  • 83 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2023.

Based on Quantbot Technologies's 13F filing for Q4 2023, filed 14 Feb 2024.